Literature DB >> 33990145

Effect of focused cardiopulmonary ultrasonography on clinical outcome of septic shock: a randomized study.

Li Li1, Yuhang Ai1, Xiaoting Wang2, Hongmin Zhang2, Xinhua Ma1, Li Huang1, Meilin Ai1, Qianyi Peng1, Lina Zhang1.   

Abstract

OBJECTIVE: To investigate the effect of focused ultrasonography on clinical outcomes of septic shock.
METHODS: Patients with septic shock were randomized into an integrated cardiopulmonary ultrasonography (ICUS) group and conventional (CON) group. Within 1 hour of admission, the ICUS group underwent ICUS examination for hemodynamic decision-making, while the CON group received standard treatment. The primary endpoint was 28-day mortality after admission. The secondary endpoints were cumulative fluid administration in the first 6, 24, and 72 hours; use of vasoactive drugs; lactate clearance; duration of ventilation; and ICU stay.
RESULTS: Ninety-four qualified patients were enrolled (ICUS group, 49; CON group, 45). ICUS showed no significant effect on 28-day mortality. Within the initial 6 hours, the ICUS group tended to have a higher fluid balance and fluid intake than the CON group. The duration of vasopressor support was shorter in the ICUS group. There were no differences in the cumulative fluid infusion within 24 or 72 hours, lactate clearance, ICU stay, or duration of ventilation.
CONCLUSIONS: The initially focused ICUS did not affect the clinical outcomes of septic shock, but it tended to be associated with a higher fluid balance within the initial 6 hours and shorter duration of vasopressor support.

Entities:  

Keywords:  Focused ultrasonography; clinical outcome; early goal-directed therapy; hemodynamic monitoring; septic shock; severe sepsis

Year:  2021        PMID: 33990145     DOI: 10.1177/03000605211013176

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  1 in total

1.  Goal-directed therapy in sepsis strikes back.

Authors:  Stefano Skurzak; Mauro Gallo; Bruna Lavezzo; Sara Iannandrea; Roberto Balagna
Journal:  Intensive Care Med       Date:  2021-11-08       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.